Research Article
Hierarchical Bayesian approaches to phase II trials in diseases with multiple subtypes
Abstract
We propose a methodology for conducting phase II clinical trials in settings where the disease is categorized into multiple subtypes. A hierarchical Bayesian model is assumed for treatment effects within the subtypes. The hierarchical model, which is tailored to each particular application, allows treatment effects to differ across subtypes while assuming a priori that the effects are exchangeable and correlated. Two applications are described. The first is a trial of imatinib for sarcoma in which treatment activity is characterized by a binary indicator of tumour response. The second is a phase II trial of a new preparative regimen for allogeneic bone marrow transplantation in patients with haematologic malignancies, with treatment effect characterized by the mean time from transplant to disease progression or death. The applications illustrate how the hierarchical Bayesian model borrows strength across subtypes. Copyright © 2003 John Wiley & Sons, Ltd.
Citing Literature
Number of times cited according to CrossRef: 83
- Ruitao Lin, J. Jack Lee, Novel Bayesian Adaptive Designs and Their Applications in Cancer Clinical Trials, Computational and Methodological Statistics and Biostatistics, 10.1007/978-3-030-42196-0_17, (395-426), (2020).
- Boris Freidlin, Edward L. Korn, Adaptive Phase II Trials, Principles and Practice of Clinical Trials, 10.1007/978-3-319-52677-5, (1-13), (2020).
- Tasos Papanikos, John R. Thompson, Keith R. Abrams, Nicolas Städler, Oriana Ciani, Rod Taylor, Sylwia Bujkiewicz, Bayesian hierarchical meta‐analytic methods for modeling surrogate relationships that vary across treatment classes using aggregate data, Statistics in Medicine, 10.1002/sim.8465, 39, 8, (1103-1124), (2020).
- Jin Jin, Marie‐Karelle Riviere, Xiaodong Luo, Yingwen Dong, Bayesian methods for the analysis of early‐phase oncology basket trials with information borrowing across cancer types, Statistics in Medicine, 10.1002/sim.8675, 39, 25, (3459-3475), (2020).
- Veronica Bunn, Rachael Liu, Junjing Lin, Jianchang Lin, Flexible Bayesian subgroup analysis in early and confirmatory trials, Contemporary Clinical Trials, 10.1016/j.cct.2020.106149, 98, (106149), (2020).
- Tianjian Zhou, Yuan Ji, RoBoT: a robust Bayesian hypothesis testing method for basket trials, Biostatistics, 10.1093/biostatistics/kxaa005, (2020).
- Xiao Song, Kevin K Dobbin, Evaluating biomarkers for treatment selection from reproducibility studies, Biostatistics, 10.1093/biostatistics/kxaa019, (2020).
- Jin Jin, Qianying Liu, Wei Zheng, Zhenming Shun, Tun Tun Lin, Lei Gao, Yingwen Dong, A Bayesian Method for the Detection of Proof of Concept in Early Phase Oncology Studies with a Basket Design, Statistics in Biosciences, 10.1007/s12561-020-09267-2, (2020).
- Junichi Asano, Akihiro Hirakawa, A Bayesian basket trial design accounting for uncertainties of homogeneity and heterogeneity of treatment effect among subpopulations, Pharmaceutical Statistics, 10.1002/pst.2049, 0, 0, (2020).
- Guosheng Yin, Zhao Yang, Motoi Odani, Satoru Fukimbara, Bayesian Hierarchical Modeling and Biomarker Cutoff Identification in Basket Trials, Statistics in Biopharmaceutical Research, 10.1080/19466315.2020.1811146, (1-22), (2020).
- Tze Leung Lai, Michael Sklar, Nikolas Thomas Weissmueller, Novel Clinical Trial Designs and Statistical Methods in the Era of Precision Medicine, Statistics in Biopharmaceutical Research, 10.1080/19466315.2020.1814403, (1-39), (2020).
- Menghao Xu, Ting Ye, Jun-jun Zhao, Menggang Yu, Sample Size Determination for Stratified Phase II Cancer Trials With Monotone Order Constraints, Statistics in Biopharmaceutical Research, 10.1080/19466315.2020.1764863, (1-10), (2020).
- Nan Chen, J Jack Lee, Bayesian cluster hierarchical model for subgroup borrowing in the design and analysis of basket trials with binary endpoints, Statistical Methods in Medical Research, 10.1177/0962280220910186, (096228022091018), (2020).
- Matthew A. Psioda, Kuolung Hu, Yang Zhang, Jean Pan, Joseph G. Ibrahim, Bayesian design of biosimilars clinical programs involving multiple therapeutic indications, Biometrics, 10.1111/biom.13163, 76, 2, (630-642), (2019).
- Kei Fujikawa, Satoshi Teramukai, Isao Yokota, Takashi Daimon, A Bayesian basket trial design that borrows information across strata based on the similarity between the posterior distributions of the response probability, Biometrical Journal, 10.1002/bimj.201800404, 62, 2, (330-338), (2019).
- Peter F. Thall, Bayesian cancer clinical trial designs with subgroup-specific decisions, Contemporary Clinical Trials, 10.1016/j.cct.2019.105860, (105860), (2019).
- Daniel J. DeAngelo, Alison R. Walker, Richard F. Schlenk, Jorge Sierra, Bruno C. Medeiros, Enrique M. Ocio, Christoph Röllig, Stephen A. Strickland, Felicitas Thol, Sue-zette Valera, Kohinoor Dasgupta, Noah Berkowitz, Robert K. Stuart, Safety and efficacy of oral panobinostat plus chemotherapy in patients aged 65 years or younger with high-risk acute myeloid leukemia, Leukemia Research, 10.1016/j.leukres.2019.106197, (106197), (2019).
- Akihiro Hirakawa, Junichi Asano, Hiroyuki Sato, Satoshi Teramukai, Cancer Clinical Trials Based on Master Protocolマスタープロトコルに基づくがん臨床試験, Japanese Journal of Biometrics, 10.5691/jjb.39.85, 39, 2, (85-101), (2019).
- Akihiro Hirakawa, Junichi Asano, Hiroyuki Sato, Hiroya Hashimoto, Satoshi Teramukai, Bayesian Basket Designs for Cancer Clinical Trialsがん臨床試験におけるベイズ流バスケットデザインの理論と実装, Japanese Journal of Biometrics, 10.5691/jjb.39.103, 39, 2, (103-122), (2019).
- Heng Zhou, Fang Liu, Cai Wu, Eric H. Rubin, Vincent L. Giranda, Cong Chen, Optimal two-stage designs for exploratory basket trials, Contemporary Clinical Trials, 10.1016/j.cct.2019.06.021, (105807), (2019).
- Laura M. Yee, Lisa M. McShane, Boris Freidlin, Margaret M. Mooney, Edward L. Korn, Biostatistical and Logistical Considerations in the Development of Basket and Umbrella Clinical Trials, The Cancer Journal, 10.1097/PPO.0000000000000384, 25, 4, (254-263), (2019).
- Yong Zang, Beibei Guo, Yan Han, Sha Cao, Chi Zhang, A Bayesian adaptive marker‐stratified design for molecularly targeted agents with customized hierarchical modeling, Statistics in Medicine, 10.1002/sim.8159, 38, 15, (2883-2896), (2019).
- Chen Hu, James J. Dignam, Biomarker-Driven Oncology Clinical Trials: Key Design Elements, Types, Features, and Practical Considerations, JCO Precision Oncology, 10.1200/PO.19.00086, 3, (1-12), (2019).
- Alexander M. Kaizer, Joseph S. Koopmeiners, Michael J. Kane, Satrajit Roychoudhury, David S. Hong, Brian P. Hobbs, Basket Designs: Statistical Considerations for Oncology Trials, JCO Precision Oncology, 10.1200/PO.19.00194, 3, (1-9), (2019).
- Matthew A Psioda, Jiawei Xu, Qi Jiang, Chunlei Ke, Zhao Yang, Joseph G Ibrahim, Bayesian adaptive basket trial design using model averaging, Biostatistics, 10.1093/biostatistics/kxz014, (2019).
- Lili Zhao, Carl Koschmann, Integrating subgroups with mixed-type endpoints in early phase oncology trials, Statistical Methods in Medical Research, 10.1177/0962280219840050, (096228021984005), (2019).
- Yu-Mei Chang, Pao-Sheng Shen, Ken-Ning Hsu, Two-Arm Comparisons in Two-Stage Designs for Stratified Randomized Phase II Trials, Statistics in Biopharmaceutical Research, 10.1080/19466315.2019.1573701, (1-12), (2019).
- Nan Chen, J. Jack Lee, Bayesian hierarchical classification and information sharing for clinical trials with subgroups and binary outcomes, Biometrical Journal, 10.1002/bimj.201700275, 61, 5, (1219-1231), (2018).
- B. Cabarrou, P. Sfumato, E. Leconte, J.M. Boher, T. Filleron, Designing phase II clinical trials to target subgroup of interest in a heterogeneous population: A case study using an R package, Computers in Biology and Medicine, 10.1016/j.compbiomed.2018.06.034, 100, (239-246), (2018).
- Akihiro Hirakawa, Junichi Asano, Hiroyuki Sato, Satoshi Teramukai, Master protocol trials in oncology: Review and new trial designs, Contemporary Clinical Trials Communications, 10.1016/j.conctc.2018.08.009, 12, (1-8), (2018).
- Yiyi Chu, Ying Yuan, BLAST: Bayesian latent subgroup design for basket trials accounting for patient heterogeneity, Journal of the Royal Statistical Society: Series C (Applied Statistics), 10.1111/rssc.12255, 67, 3, (723-740), (2018).
- Brian P. Hobbs, Rick Landin, Bayesian basket trial design with exchangeability monitoring, Statistics in Medicine, 10.1002/sim.7893, 37, 25, (3557-3572), (2018).
- Yiyi Chu, Ying Yuan, A Bayesian basket trial design using a calibrated Bayesian hierarchical model, Clinical Trials, 10.1177/1740774518755122, 15, 2, (149-158), (2018).
- Beibei Guo, Yong Zang, A Bayesian adaptive phase II clinical trial design accounting for spatial variation, Statistical Methods in Medical Research, 10.1177/0962280218797149, (096228021879714), (2018).
- Richard Simon, New designs for basket clinical trials in oncology, Journal of Biopharmaceutical Statistics, 10.1080/10543406.2017.1372779, 28, 2, (245-255), (2017).
- Jun Yin, Rui Qin, Daniel J. Sargent, Charles Erlichman, Qian Shi, A hierarchical Bayesian design for randomized Phase II clinical trials with multiple groups, Journal of Biopharmaceutical Statistics, 10.1080/10543406.2017.1321007, 28, 3, (451-462), (2017).
- Kazushi Maruo, Keisuke Tada, Ryota Ishii, Masahiko Gosho, An Efficient Procedure for Calculating Sample Size Through Statistical Simulations, Statistics in Biopharmaceutical Research, 10.1080/19466315.2017.1349689, 10, 1, (1-8), (2017).
- Natacha Omer, Marie-Cécile Le Deley, Sophie Piperno-Neumann, Perrine Marec-Berard, Antoine Italiano, Nadège Corradini, Carine Bellera, Laurence Brugières, Nathalie Gaspar, Phase-II trials in osteosarcoma recurrences: A systematic review of past experience, European Journal of Cancer, 10.1016/j.ejca.2017.01.005, 75, (98-108), (2017).
- William T. Barry, Trial Designs and Biostatistics for Molecular-Targeted Agents, Breast Cancer, 10.1007/978-3-319-48848-6, (915-924), (2017).
- Steffen Ventz, William T. Barry, Giovanni Parmigiani, Lorenzo Trippa, Bayesian response‐adaptive designs for basket trials, Biometrics, 10.1111/biom.12668, 73, 3, (905-915), (2017).
- Kristen M. Cunanan, Alexia Iasonos, Ronglai Shen, Colin B. Begg, Mithat Gönen, An efficient basket trial design, Statistics in Medicine, 10.1002/sim.7227, 36, 10, (1568-1579), (2017).
- Shinjo Yada, Chikuma Hamada, Analyses of drug combinations using missing data shortens trial periods in phase I/II oncology trials, Contemporary Clinical Trials Communications, 10.1016/j.conctc.2017.05.011, 7, (73-80), (2017).
- Kristen M. Cunanan, Alexia Iasonos, Ronglai Shen, David M. Hyman, Gregory J. Riely, Mithat Gönen, Colin B. Begg, Specifying the True- and False-Positive Rates in Basket Trials, JCO Precision Oncology, 10.1200/PO.17.00181, 1, (1-5), (2017).
- T. Christopher Windham, Peter W. T. Pisters, Retroperitoneal Sarcomas, Cancer Control, 10.1177/107327480501200105, 12, 1, (36-43), (2017).
- Kristen M Cunanan, Joseph S Koopmeiners, Hierarchical models for sharing information across populations in phase I dose-escalation studies, Statistical Methods in Medical Research, 10.1177/0962280217703812, (096228021770381), (2017).
- Shinjo Yada, Chikuma Hamada, Application of Bayesian hierarchical models for phase I/II clinical trials in oncology, Pharmaceutical Statistics, 10.1002/pst.1793, 16, 2, (114-121), (2016).
- Lindsay A. Renfro, Himel Mallick, Ming-Wen An, Daniel J. Sargent, Sumithra J. Mandrekar, Clinical trial designs incorporating predictive biomarkers, Cancer Treatment Reviews, 10.1016/j.ctrv.2015.12.008, 43, (74-82), (2016).
- Richard Simon, Martine Piccart‐Gebhart, Biomarker‐Based Clinical Trial Design in the Era of Genomic Medicine, Holland‐Frei Cancer Medicine, 10.1002/9781119000822, (1-6), (2016).
- J. Jack Lee, Donald A. Berry, Statistical Innovations in Cancer Research, Holland‐Frei Cancer Medicine, 10.1002/9781119000822, (1-18), (2016).
- Richard Simon, Susan Geyer, Jyothi Subramanian, Sameek Roychowdhury, The Bayesian basket design for genomic variant-driven phase II trials, Seminars in Oncology, 10.1053/j.seminoncol.2016.01.002, 43, 1, (13-18), (2016).
- Cong Chen, Xiaoyun (Nicole) Li, Shuai Yuan, Zoran Antonijevic, Rasika Kalamegham, Robert A. Beckman, Statistical Design and Considerations of a Phase 3 Basket Trial for Simultaneous Investigation of Multiple Tumor Types in One Study, Statistics in Biopharmaceutical Research, 10.1080/19466315.2016.1193044, 8, 3, (248-257), (2016).
- H F McFarland, S C Reingold, The future of multiple sclerosis therapies: redesigning multiple sclerosis clinical trials in a new therapeutic eraa, Multiple Sclerosis Journal, 10.1191/1352458505ms1231oa, 11, 6, (669-676), (2016).
- Peter F Thall, Leiko H Wooten, Nizar M Tannir, Monitoring event times in early phase clinical trials: some practical issues, Clinical Trials: Journal of the Society for Clinical Trials, 10.1191/1740774505cn121oa, 2, 6, (467-478), (2016).
- Beat Neuenschwander, Simon Wandel, Satrajit Roychoudhury, Stuart Bailey, Robust exchangeability designs for early phase clinical trials with multiple strata, Pharmaceutical Statistics, 10.1002/pst.1730, 15, 2, (123-134), (2015).
- Scott M. Schuetze, J. Kyle Wathen, David R. Lucas, Edwin Choy, Brian L. Samuels, Arthur P. Staddon, Kristen N. Ganjoo, Margaret von Mehren, Warren A. Chow, David M. Loeb, Hussein A. Tawbi, Daniel A. Rushing, Shreyaskumar R. Patel, Dafydd G. Thomas, Rashmi Chugh, Denise K. Reinke, Laurence H. Baker, SARC009: Phase 2 study of dasatinib in patients with previously treated, high‐grade, advanced sarcoma, Cancer, 10.1002/cncr.29858, 122, 6, (868-874), (2015).
- Nisha Mohindra, Mark Agulnik, Targeted therapy and promising novel agents for the treatment of advanced soft tissue sarcomas, Expert Opinion on Investigational Drugs, 10.1517/13543784.2015.1076792, 24, 11, (1409-1418), (2015).
- William T. Barry, Charles M. Perou, P. Kelly Marcom, Lisa A. Carey, Joseph G. Ibrahim, The Use of Bayesian Hierarchical Models for Adaptive Randomization in Biomarker-Driven Phase II Studies, Journal of Biopharmaceutical Statistics, 10.1080/10543406.2014.919933, 25, 1, (66-88), (2015).
- Aaron Dane, Jeffrey D. Wetherington, Statistical considerations associated with a comprehensive regulatory framework to address the unmet need for new antibacterial therapies, Pharmaceutical Statistics, 10.1002/pst.1625, 13, 4, (222-228), (2014).
- Andre C. Kalil, Junfeng Sun, Bayesian Methodology for the Design and Interpretation of Clinical Trials in Critical Care Medicine, Critical Care Medicine, 10.1097/CCM.0000000000000576, 42, 10, (2267-2277), (2014).
- Sarah R. Brown, Walter M. Gregory, Chris Twelves, Julia Brown, References, A Practical Guide to Designing Phase II Trials in Oncology, 10.1002/9781118763612, (213-225), (2014).
- Michelle Fanale, Sarit Assouline, John Kuruvilla, Philippe Solal‐Céligny, Dae S. Heo, Gregor Verhoef, Paolo Corradini, Jeremy S. Abramson, Fritz Offner, Andreas Engert, Martin J. S. Dyer, Daniel Carreon, Brett Ewald, Johan Baeck, Anas Younes, Arnold S. Freedman, Phase IA/II, multicentre, open‐label study of the CD40 antagonistic monoclonal antibody lucatumumab in adult patients with advanced non‐Hodgkin or Hodgkin lymphoma, British Journal of Haematology, 10.1111/bjh.12630, 164, 2, (258-265), (2013).
- Scott M Berry, Kristine R Broglio, Susan Groshen, Donald A Berry, Bayesian hierarchical modeling of patient subpopulations: Efficient designs of Phase II oncology clinical trials, Clinical Trials: Journal of the Society for Clinical Trials, 10.1177/1740774513497539, 10, 5, (720-734), (2013).
- Myron N. Chang, Jonathan J. Shuster, Wei Hou, Improved two‐stage tests for stratified phase II cancer clinical trials, Statistics in Medicine, 10.1002/sim.5314, 31, 16, (1688-1698), (2012).
- John Crowley, References, Clinical Trials in Oncology, Third Edition, 10.1201/b12125-13, (223-241), (2012).
- Michael LeBlanc, Cathryn Rankin, John Crowley, John Crowley, Antje Hoering, Phase II with Multiple Subgroups, Handbook of Statistics in Clinical Oncology, Third Edition, 10.1201/b11800, (163-174), (2012).
- Caroline Tournoux‐Facon, Yann De Rycke, Pascale Tubert‐Bitter, Targeting population entering phase III trials: A new stratified adaptive phase II design, Statistics in Medicine, 10.1002/sim.4148, 30, 8, (801-811), (2011).
- Myron Chang, Sin-Ho Jung, Samuel S. Wu, Two-Stage Designs with Additional Futility Tests for Phase II Clinical Trials with Heterogeneous Patient Populations, Sequential Analysis, 10.1080/07474946.2011.593924, 30, 3, (338-349), (2011).
- Richard Sposto, Paul S. Gaynon, An adjustment for patient heterogeneity in the design of two‐stage phase II trials, Statistics in Medicine, 10.1002/sim.3624, 28, 20, (2566-2579), (2009).
- Rashmi Chugh, J. Kyle Wathen, Robert G. Maki, Robert S. Benjamin, Shreyaskumar R. Patel, Paul A. Myers, Dennis A. Priebat, Denise K. Reinke, Dafydd G. Thomas, Mary L. Keohan, Brian L. Samuels, Laurence H. Baker, Phase II Multicenter Trial of Imatinib in 10 Histologic Subtypes of Sarcoma Using a Bayesian Hierarchical Statistical Model, Journal of Clinical Oncology, 10.1200/JCO.2008.20.5054, 27, 19, (3148-3153), (2009).
- Peter F Thall, J Kyle Wathen, Bayesian designs to account for patient heterogeneity in phase II clinical trials, Current Opinion in Oncology, 10.1097/CCO.0b013e328302163c, 20, 4, (407-411), (2008).
- J. Kyle Wathen, Peter F. Thall, John D. Cook, Elihu H. Estey, Accounting for patient heterogeneity in phase II clinical trials, Statistics in Medicine, 10.1002/sim.3109, 27, 15, (2802-2815), (2007).
- Mark R. Gilbert, Designing clinical trials for brain tumors: The next generation, Current Oncology Reports, 10.1007/BF02951425, 9, 1, (49-54), (2007).
- Kenneth R. Hess, Statistical issues in clinical trial design, Current Oncology Reports, 10.1007/BF02951426, 9, 1, (55-59), (2007).
- Feng Gao, Kathryn Trinkaus, J. Philip Miller, 17 Early Phase Clinical Trials: Phases I and II, Epidemiology and Medical Statistics, 10.1016/S0169-7161(07)27017-8, (513-545), (2007).
- Stephen Reingold, Henry McFarland, Alternative designs for multiple sclerosis clinical trials, Multiple Sclerosis Therapeutics, Third Edition, 10.3109/9780203012055, (331-341), (2007).
- David M. Vail, Cancer Clinical Trials: Development and Implementation, Veterinary Clinics of North America: Small Animal Practice, 10.1016/j.cvsm.2007.06.007, 37, 6, (1033-1057), (2007).
- T. Christopher Windham, Vernon K. Sondak, Soft Tissue Sarcoma, Oncology, 10.1007/0-387-31056-8, (1048-1081), (2006).
- Deborah Ashby, Bayesian statistics in medicine: a 25 year review, Statistics in Medicine, 10.1002/sim.2672, 25, 21, (3589-3631), (2006).
- Stefan Sleijfer, Caroline Seynaeve, Jaap Verweij, Using Single‐Agent Therapy in Adult Patients with Advanced Soft Tissue Sarcoma Can Still Be Considered Standard Care, The Oncologist, 10.1634/theoncologist.10-10-833, 10, 10, (833-841), (2005).
- J. Jack Lee, Clinical Trial Design for Anticancer Therapies, The Cancer Handbook, 10.1002/0470025077, (2005).
- Alberto S. Pappo, Meenakshi Devidas, Jessee Jenkins, Bhaskar Rao, Robert Marcus, Patrick Thomas, Mark Gebhardt, Charles Pratt, Holcombe E. Grier, Phase II Trial of Neoadjuvant Vincristine, Ifosfamide, and Doxorubicin With Granulocyte Colony-Stimulating Factor Support in Children and Adolescents With Advanced-Stage Nonrhabdomyosarcomatous Soft Tissue Sarcomas: A Pediatric Oncology Group Study, Journal of Clinical Oncology, 10.1200/JCO.2005.03.209, 23, 18, (4031-4038), (2005).
- J. Jack Lee, Lei Feng, Randomized Phase II Designs in Cancer Clinical Trials: Current Status and Future Directions, Journal of Clinical Oncology, 10.1200/JCO.2005.03.197, 23, 19, (4450-4457), (2005).
- Rashmi Chugh, Rodney Dunn, Mark M. Zalupski, J. Sybil Biermann, Vernon K. Sondak, Joseph R. Mace, Kirsten M. Leu, William F. Chandler, Laurence H. Baker, Phase II Study of 9-Nitro-Camptothecin in Patients With Advanced Chordoma or Soft Tissue Sarcoma, Journal of Clinical Oncology, 10.1200/JCO.2005.02.170, 23, 15, (3597-3604), (2005).
